Artiva Biotherapeutics, Inc. ARTV Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$23.52M-15.8% | -$20.77M-29.1% | -$21.53M-23.2% | -$21.25M-19.1% | -$20.31M-45.5% | ||
| $666K+6.1% | $666K+8.5% | $662K+5.6% | $641K+6.3% | $628K+7.0% | ||
| $1.59M-22.4% | $1.59M-27.2% | $1.63M-14.5% | $1.55M+4.5% | $2.05M+45.9% | ||
| —— | -$0+100% | -$0— | -$0+100% | -$0+100% | ||
| $1.81M+4,320% | -$150K— | -$442K-163% | -$209K+78.1% | $41K-95.2% | ||
| -$4M-330% | $2.37M+338% | $1.12M-63.9% | -$550K— | -$931K+69.4% | ||
| —— | $40K+229% | $380K+1,288% | $25K+181% | -$254K-719% | ||
| -$67K-176% | -$12K— | —— | -$204K— | $88K-51.1% | ||
| -$20.95M-5.6% | -$14.73M-0.5% | -$19.2M-65.4% | -$22.98M-67.9% | -$19.84M-31.5% | ||
| $242K-52.6% | $421K+558% | $600K+525% | $1.06M+127% | $511K+2,739% | ||
| $6.44M-65.2% | $7.54M-49.2% | $12.75M-91.1% | $6.07M-50.2% | $18.52M+199% | ||
| $22M-24.1% | $24M+72.0% | $29.62M+139% | $28.25M+102% | $29M+81.3% | ||
| $15.32M+53.6% | $16.04M+1,760% | $16.28M+112% | $21.12M+1,466% | $9.97M+1.9% | ||
| —— | -$138K— | —— | —— | $138K— | ||
| $33K0.0% | $34K+3.0% | $32K-15.8% | $33K— | $33K— | ||
| -$112K-147% | —— | —— | —— | $239K— | ||
| -$5.75M+40.3% | $0+100% | -$2.96M-114% | -$1.93M+86.1% | -$9.63M-81.6% | ||
| $199K-72.5% | $291K-72.1% | $357K-45.8% | $509K+86.4% | $723K+96.5% | ||
| -$3K+76.9% | —— | -$51K— | $34K-60.0% | -$13K-129% | ||
| -$67K-176% | -$12K— | —— | -$204K— | $88K-51.1% | ||
| -$2.63M-451% | —— | —— | $2.86M— | $750K-19.9% | ||
| —— | $0— | $0+100% | $0+100% | $0+100% | ||
| $22M-24.1% | $24M+72.0% | $29.62M+139% | $28.25M+102% | $29M+81.3% | ||
| $33K0.0% | $34K+3.0% | $32K-15.8% | $33K— | $33K— | ||
| —— | -$0-100% | -$0-100% | -$0— | -$0— | ||
| -$131K+2.2% | —— | -$99K— | —— | -$134K— | ||
| $298K-66.2% | —— | $143K— | —— | $882K+6,685% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | $442K— | ||
| -$21.19M-4.1% | -$15.15M-2.9% | -$19.8M-69.1% | -$24.04M-69.9% | -$20.35M-34.7% | ||
| -$21.19M-4.1% | -$15.15M-2.9% | -$19.8M-69.1% | -$24.04M-69.9% | -$20.35M-34.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Artiva Biotherapeutics, Inc. generate?
- Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
- What is Artiva Biotherapeutics, Inc.'s free cash flow?
- After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
- Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.